

# Stephen Finn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6524694/publications.pdf>

Version: 2024-02-01

155  
papers

7,827  
citations

53794

45  
h-index

58581

82  
g-index

160  
all docs

160  
docs citations

160  
times ranked

14304  
citing authors

#	ARTICLE	IF	CITATIONS
1	CDK8 is a colorectal cancer oncogene that regulates $\beta^2$ -catenin activity. <i>Nature</i> , 2008, 455, 547-551.	27.8	594
2	Circular RNAs: Biogenesis, Function and Role in Human Diseases. <i>Frontiers in Molecular Biosciences</i> , 2017, 4, 38.	3.5	449
3	Gleason Score and Lethal Prostate Cancer: Does 3 + 4 = 4 + 3?. <i>Journal of Clinical Oncology</i> , 2009, 27, 3459-3464.	1.6	329
4	Fatty Acid Synthase: A Metabolic Enzyme and Candidate Oncogene in Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2009, 101, 519-532.	6.3	328
5	Potential role of miR-9 and miR-223 in recurrent ovarian cancer. <i>Molecular Cancer</i> , 2008, 7, 35.	19.2	269
6	Identification of the JNK Signaling Pathway as a Functional Target of the Tumor Suppressor PTEN. <i>Cancer Cell</i> , 2007, 11, 555-569.	16.8	214
7	Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. <i>Nature Biotechnology</i> , 2009, 27, 77-83.	17.5	210
8	Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways. , 2016, 158, 71-90.		166
9	B-Raf <sup>V600E</sup> and thrombospondin-1 promote thyroid cancer progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 10649-10654.	7.1	164
10	A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 108, djv346.	6.3	149
11	Long Non-Coding RNAs: Key Regulators of Epithelial-Mesenchymal Transition, Tumour Drug Resistance and Cancer Stem Cells. <i>Cancers</i> , 2017, 9, 38.	3.7	143
12	Platelet Adhesion and Degranulation Induce Pro-Survival and Pro-Angiogenic Signalling in Ovarian Cancer Cells. <i>PLoS ONE</i> , 2011, 6, e26125.	2.5	141
13	mRNA Expression Signature of Gleason Grade Predicts Lethal Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2391-2396.	1.6	140
14	Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel. <i>European Journal of Cancer</i> , 2014, 50, 1617-1627.	2.8	133
15	Lung cancer stem cells: The root of resistance. <i>Cancer Letters</i> , 2016, 372, 147-156.	7.2	130
16	The Isopeptidase USP2a Protects Human Prostate Cancer from Apoptosis. <i>Cancer Research</i> , 2006, 66, 8625-8632.	0.9	129
17	Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of $\beta^2$ -catenin in prostate cancer. <i>Laboratory Investigation</i> , 2008, 88, 1340-1348.	3.7	116
18	The role of DNA repair pathways in cisplatin resistant lung cancer. <i>Cancer Treatment Reviews</i> , 2014, 40, 1161-1170.	7.7	114

#	ARTICLE	IF	CITATIONS
19	Fatty Acid Synthase Polymorphisms, Tumor Expression, Body Mass Index, Prostate Cancer Risk, and Survival. <i>Journal of Clinical Oncology</i> , 2010, 28, 3958-3964.	1.6	113
20	Immunohistochemical Expression of BRCA1 and Lethal Prostate Cancer. <i>Cancer Research</i> , 2010, 70, 3136-3139.	0.9	110
21	Endothelial NOS, estrogen receptor $\beta$ , and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. <i>Journal of Clinical Investigation</i> , 2009, 119, 1093-1108.	8.2	110
22	Prostate-Specific Membrane Antigen Protein Expression in Tumor Tissue and Risk of Lethal Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 2354-2363.	2.5	99
23	Targeting the fibroblast growth factor receptor family in cancer. <i>Cancer Treatment Reviews</i> , 2016, 46, 51-62.	7.7	99
24	IGF-1 and Its Receptor in Esophageal Cancer: Association with Adenocarcinoma and Visceral Obesity. <i>American Journal of Gastroenterology</i> , 2012, 107, 196-204.	0.4	96
25	Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. <i>Modern Pathology</i> , 2008, 21, 676-684.	5.5	91
26	Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer. <i>Nature Communications</i> , 2017, 8, 420.	12.8	91
27	Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol. <i>BMJ Open</i> , 2018, 8, e022899.	1.9	85
28	The emerging role of microRNAs in resistance to lung cancer treatments. <i>Cancer Treatment Reviews</i> , 2015, 41, 160-169.	7.7	83
29	Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma. <i>Modern Pathology</i> , 2009, 22, 197-205.	5.5	80
30	Modification of the Association Between Obesity and Lethal Prostate Cancer by TMPRSS2:ERG. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1881-1890.	6.3	80
31	Cleason Grade Progression Is Uncommon. <i>Cancer Research</i> , 2013, 73, 5163-5168.	0.9	76
32	<i>FOXA1</i> Is a Potential Oncogene in Anaplastic Thyroid Carcinoma. <i>Clinical Cancer Research</i> , 2009, 15, 3680-3689.	7.0	75
33	SPINK1 Protein Expression and Prostate Cancer Progression. <i>Clinical Cancer Research</i> , 2014, 20, 4904-4911.	7.0	71
34	p16INK4A genetic and epigenetic profiles differ in relation to age and site in head and neck squamous cell carcinomas. <i>Human Pathology</i> , 2008, 39, 452-458.	2.0	69
35	BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC. <i>Cancer Letters</i> , 2018, 428, 117-126.	7.2	69
36	Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. <i>Scientific Reports</i> , 2019, 9, 10739.	3.3	69

#	ARTICLE	IF	CITATIONS
37	Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscope Project. <i>Journal of Thoracic Oncology</i> , 2018, 13, 413-425.	1.1	66
38	Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. <i>American Journal of Clinical Nutrition</i> , 2016, 103, 851-860.	4.7	65
39	Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC. <i>Oncotarget</i> , 2017, 8, 72544-72563.	1.8	60
40	Effect of ret/PTC 1 rearrangement on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model. <i>Molecular Cancer</i> , 2006, 5, 70.	19.2	59
41	Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscope project. <i>Lung Cancer</i> , 2017, 111, 143-149.	2.0	57
42	Utility of multispectral imaging in automated quantitative scoring of immunohistochemistry. <i>Journal of Clinical Pathology</i> , 2012, 65, 496-502.	2.0	56
43	miR-29b Expression Is Associated With Disease-Free Survival in Patients With Ovarian Serous Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 641-647.	2.5	55
44	Genetic variation in RNASEL associated with prostate cancer risk and progression. <i>Carcinogenesis</i> , 2010, 31, 1597-1603.	2.8	54
45	Perineural Invasion and Risk of Lethal Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 719-726.	2.5	51
46	Common Polymorphisms in the Adiponectin and Its Receptor Genes, Adiponectin Levels and the Risk of Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 2618-2627.	2.5	50
47	ret/PTC and BRAF Act as Distinct Molecular, Time-Dependant Triggers in a Sporadic Irish Cohort of Papillary Thyroid Carcinoma. <i>International Journal of Surgical Pathology</i> , 2005, 13, 1-8.	0.8	43
48	Semiautomated Multiplexed Quantum Dot-Based in Situ Hybridization and Spectral Deconvolution. <i>Journal of Molecular Diagnostics</i> , 2007, 9, 20-29.	2.8	42
49	Expression microarray analysis of papillary thyroid carcinoma and benign thyroid tissue: emphasis on the follicular variant and potential markers of malignancy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2007, 450, 249-260.	2.8	41
50	Protein Expression of PTEN, Insulin-Like Growth Factor I Receptor (IGF-IR), and Lethal Prostate Cancer: A Prospective Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1984-1993.	2.5	41
51	Integrating biomarkers across omic platforms: an approach to improve stratification of patients with indolent and aggressive prostate cancer. <i>Molecular Oncology</i> , 2018, 12, 1513-1525.	4.6	41
52	A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscope Project. <i>Lung Cancer</i> , 2019, 131, 95-103.	2.0	40
53	Prostate cancer: Re-focusing on androgen receptor signaling. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 1562-1568.	2.8	37
54	Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscope Project. <i>Journal of Thoracic Oncology</i> , 2021, 16, 990-1002.	1.1	37

#	ARTICLE	IF	CITATIONS
55	The MyD88+ Phenotype Is an Adverse Prognostic Factor in Epithelial Ovarian Cancer. PLoS ONE, 2014, 9, e100816.	2.5	36
56	Distinct array comparative genomic hybridization profiles in oral squamous cell carcinoma occurring in young patients. Head and Neck, 2006, 28, 330-338.	2.0	35
57	Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. Carcinogenesis, 2018, 39, 1431-1437.	2.8	35
58	Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. Clinical Cancer Research, 2020, 26, 1086-1093.	7.0	35
59	A molecular expression signature distinguishing follicular lesions in thyroid carcinoma using preamplification RT-PCR in archival samples. Modern Pathology, 2007, 20, 1095-1102.	5.5	34
60	Carcinogenesis in prostate cancer: The role of long non-coding RNAs. Non-coding RNA Research, 2018, 3, 29-38.	4.6	33
61	The Liquid Biopsy for Lung Cancer: State of the Art, Limitations and Future Developments. Cancers, 2021, 13, 3923.	3.7	33
62	BRAF T1799A Mutation Occurring in a Case of Malignant Struma Ovarii. International Journal of Surgical Pathology, 2007, 15, 116-120.	0.8	31
63	Calcium-Sensing Receptor Tumor Expression and Lethal Prostate Cancer Progression. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2520-2527.	3.6	30
64	KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma. International Journal of Oncology, 2016, 48, 1290-1296.	3.3	30
65	The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?. Expert Opinion on Therapeutic Targets, 2016, 20, 1339-1356.	3.4	28
66	Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays™ and cross-validation with resections, in patients with, stage Iâ€“III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscope cohort. Modern Pathology, 2020, 33, 792-801.	5.5	28
67	RET Fluorescence In Situ Hybridization Analysis Is a Sensitive but Highly Unspecific Screening Method for RET Fusions in Lung Cancer. Journal of Thoracic Oncology, 2021, 16, 798-806.	1.1	28
68	A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG. European Urology, 2019, 76, 33-40.	1.9	26
69	The Node-Negative Neck: Accuracy of Clinical Intraoperative Lymph Node Assessment for Metastatic Disease in Head and Neck Cancer. Laryngoscope, 2002, 112, 630-633.	2.0	25
70	Tumor expression of adiponectin receptor 2 and lethal prostate cancer. Carcinogenesis, 2015, 36, 639-647.	2.8	25
71	Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscope Project. Annals of Oncology, 2018, 29, 200-208.	1.2	25
72	Targeting NF-Î²B-mediated inflammatory pathways in cisplatin-resistant NSCLC. Lung Cancer, 2019, 135, 217-227.	2.0	25

#	ARTICLE	IF	CITATIONS
73	Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids. <i>Journal of Nanobiotechnology</i> , 2021, 19, 71.	9.1	24
74	Ret/PTC Chimeric Transcripts in an Irish Cohort of Sporadic Papillary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 938-941.	3.6	23
75	Immunohistochemical evidence of <i>Clostridium</i> sp, <i>Staphylococcus aureus</i> , and group A <i>Streptococcus</i> in severe soft tissue infections related to injection drug use. <i>Human Pathology</i> , 2006, 37, 1482-1488.	2.0	23
76	Systems-Level Modeling of Cancer-Fibroblast Interaction. <i>PLoS ONE</i> , 2009, 4, e6888.	2.5	23
77	Pre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening. <i>International Journal of Molecular Sciences</i> , 2013, 14, 2085-2103.	4.1	23
78	Strategic targeting of the PI3K–NF- $\kappa$ B axis in cisplatin-resistant NSCLC. <i>Cancer Biology and Therapy</i> , 2014, 15, 1367-1377.	3.4	23
79	Molecular testing in oncology: Problems, pitfalls and progress. <i>Lung Cancer</i> , 2014, 83, 309-315.	2.0	23
80	In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC. <i>Oncotarget</i> , 2016, 7, 79526-79543.	1.8	23
81	Exercise and Prostate Cancer: Evidence and Proposed Mechanisms for Disease Modification. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1281-1288.	2.5	22
82	Low-Level Genomic Instability Is a Feature of Papillary Thyroid Carcinoma: An Array Comparative Genomic Hybridization Study of Laser Capture Microdissected Papillary Thyroid Carcinoma Tumors and Clonal Cell Lines. <i>Archives of Pathology and Laboratory Medicine</i> , 2007, 131, 65-73.	2.5	22
83	Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer. , 2020, 207, 107454.		21
84	Development and Progress of Ireland's Biobank Network: Ethical, Legal, and Social Implications (ELSI), Standardized Documentation, Sample and Data Release, and International Perspective. <i>Biopreservation and Biobanking</i> , 2013, 11, 3-11.	1.0	19
85	Real-time Quantitative Analysis of E-cadherin Expression in ret/PTC-1-Activated Thyroid Neoplasms. <i>International Journal of Surgical Pathology</i> , 2001, 9, 265-272.	0.8	17
86	Nodular fascitis of the maxilla in a child. <i>Journal of Oral and Maxillofacial Surgery</i> , 2000, 58, 1447-1449.	1.2	16
87	RET/PTC Rearrangements in Hashimoto's Thyroiditis. <i>International Journal of Surgical Pathology</i> , 2002, 10, 167-168.	0.8	16
88	Non-coding RNA repertoires in malignant pleural mesothelioma. <i>Lung Cancer</i> , 2015, 90, 417-426.	2.0	16
89	Pathology-Driven Comprehensive Proteomic Profiling of the Prostate Cancer Tumor Microenvironment. <i>Molecular Cancer Research</i> , 2017, 15, 281-293.	3.4	16
90	Extraction and Quantification of Sinapinic Acid from Irish Rapeseed Meal and Assessment of Angiotensin-I Converting Enzyme (ACE-I) Inhibitory Activity. <i>Journal of Agricultural and Food Chemistry</i> , 2017, 65, 6886-6892.	5.2	16

#	ARTICLE	IF	CITATIONS
91	RET/PTC Rearrangement Occurring in Primary Peritoneal Carcinoma. International Journal of Surgical Pathology, 2009, 17, 187-197.	0.8	15
92	Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer. Molecular Cancer Research, 2015, 13, 1431-1440.	3.4	15
93	The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer. Diagnostics, 2016, 6, 27.	2.6	15
94	Investigating the role of the IGF axis as a predictor of biochemical recurrence in prostate cancer patients post-surgery. Prostate, 2017, 77, 1288-1300.	2.3	15
95	RNAs as Candidate Diagnostic and Prognostic Markers of Prostate Cancer—From Cell Line Models to Liquid Biopsies. Diagnostics, 2018, 8, 60.	2.6	15
96	Deep Learning of Histopathological Features for the Prediction of Tumour Molecular Genetics. Diagnostics, 2021, 11, 1406.	2.6	15
97	Array comparative genomic hybridisation analysis of gamma-irradiated human thyrocytes. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 445, 396-404.	2.8	14
98	RET protein expression in papillary renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 900-905.	1.6	14
99	Optimising translational oncology in clinical practice: Strategies to accelerate progress in drug development. Cancer Treatment Reviews, 2015, 41, 129-135.	7.7	14
100	Diagnostic Strategies for Treatment Selection in Advanced Prostate Cancer. Diagnostics, 2021, 11, 345.	2.6	14
101	Longitudinal analysis of individual cfDNA methylome patterns in metastatic prostate cancer. Clinical Epigenetics, 2021, 13, 168.	4.1	14
102	DNA Repair Biomarkers XPF and Phospho-MAPKAP Kinase 2 Correlate with Clinical Outcome in Advanced Head and Neck Cancer. PLoS ONE, 2014, 9, e102112.	2.5	14
103	High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients. Melanoma Research, 2015, 25, 189-199.	1.2	13
104	Golgi phosphoprotein 2 (GOLPH2) is a novel bile acid-responsive modulator of oesophageal cell migration and invasion. British Journal of Cancer, 2015, 113, 1332-1342.	6.4	13
105	Deoxycholic acid promotes development of gastroesophageal reflux disease and Barrett's oesophagus by modulating integrin $\alpha$ v trafficking. Journal of Cellular and Molecular Medicine, 2017, 21, 3612-3625.	3.6	13
106	Evaluating liquid biopsies for methylomic profiling of prostate cancer. Epigenetics, 2020, 15, 715-727.	2.7	13
107	Platelet cloaking of circulating tumour cells in patients with metastatic prostate cancer: Results from ExPeCT, a randomised controlled trial. PLoS ONE, 2020, 15, e0243928.	2.5	13
108	Angioinvasive aspergillosis presenting as neutropenic colitis. Histopathology, 2006, 49, 440-441.	2.9	12



#	ARTICLE	IF	CITATIONS
109	Surgical Feasibility Study of a Novel Polytetrafluoroethylene Graft Design for the Treatment of Peripheral Arterial Disease. <i>Annals of Vascular Surgery</i> , 2007, 21, 611-617.	0.9	12
110	Profiling the tumor microenvironment proteome in prostate cancer using laser capture microdissection coupled to LC-MS/MS. A technical report. <i>EuPA Open Proteomics</i> , 2016, 10, 19-23.	2.5	12
111	Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma. <i>International Journal of Oncology</i> , 2017, 50, 1044-1052.	3.3	12
112	Exploitation of the vitamin A/retinoic acid axis depletes ALDH1-positive cancer stem cells and re-sensitises resistant non-small cell lung cancer cells to cisplatin. <i>Translational Oncology</i> , 2021, 14, 101025.	3.7	12
113	Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise. <i>Diagnostics</i> , 2022, 12, 124.	2.6	12
114	Sniffing out significant $\rho$ values: genome wide association study of asparagus anosmia. <i>BMJ, The</i> , 2016, 355, i6071.	6.0	11
115	Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer. <i>Cancer</i> , 2017, 123, 4130-4138.	4.1	11
116	Feature fusion of Raman chemical imaging and digital histopathology using machine learning for prostate cancer detection. <i>Analyst, The</i> , 2021, 146, 4195-4211.	3.5	11
117	Differential CircRNA Expression Signatures May Serve as Potential Novel Biomarkers in Prostate Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 605686.	3.7	11
118	Circulating Tumour Cell Numbers Correlate with Platelet Count and Circulating Lymphocyte Subsets in Men with Advanced Prostate Cancer: Data from the ExPeCT Clinical Trial (CTRIAL-IE 15-21). <i>Cancers</i> , 2021, 13, 4690.	3.7	11
119	The Notch-3 receptor: A molecular switch to tumorigenesis?. <i>Cancer Treatment Reviews</i> , 2017, 60, 69-76.	7.7	10
120	When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?. <i>Frontiers in Endocrinology</i> , 2019, 10, 89.	3.5	10
121	Cost-Efficient and Easy to Perform PCR-Based Assay to Identify Met Exon 14 Skipping in Formalin-Fixed Paraffin-Embedded (FFPE) Non-Small Cell Lung Cancer (NSCLC) Samples. <i>Diagnostics</i> , 2019, 9, 13.	2.6	10
122	Prostate cancer-derived holoclones: a novel and effective model for evaluating cancer stemness. <i>Scientific Reports</i> , 2020, 10, 11329.	3.3	10
123	Pathogenic BRCA Variants as Biomarkers for Risk in Prostate Cancer. <i>Cancers</i> , 2021, 13, 5697.	3.7	10
124	Inflammation and Prostate Cancer: A Multidisciplinary Approach to Identifying Opportunities for Treatment and Prevention. <i>Cancers</i> , 2022, 14, 1367.	3.7	10
125	Development and characterisation of a panel of phosphatidylinositol 3-kinase $\alpha$ mammalian target of rapamycin inhibitor resistant lung cancer cell lines. <i>Scientific Reports</i> , 2018, 8, 1652.	3.3	9
126	Nucleic acid microarrays: an overview. <i>Current Diagnostic Pathology</i> , 2003, 9, 155-158.	0.4	8



#	ARTICLE	IF	CITATIONS
127	ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib. Lung Cancer, 2019, 138, 13-18.	2.0	8
128	Multiplex profiling identifies clinically relevant signalling proteins in an isogenic prostate cancer model of radioresistance. Scientific Reports, 2019, 9, 17325.	3.3	8
129	Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110426.	3.2	8
130	MicroRNA expression profiling and biomarker validation in treatment-naïve and drug resistant non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 1773-1791.	2.8	7
131	Cannonball metastases with favourable prognosis. Irish Journal of Medical Science, 2005, 174, 61-64.	1.5	6
132	The ExPeCT (Examining Exercise, Prostate Cancer and Circulating Tumour Cells) trial: study protocol for a randomised controlled trial. Trials, 2017, 18, 456.	1.6	6
133	Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry â€” Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort. Journal of Thoracic Oncology, 2018, 13, 1851-1863.	1.1	6
134	Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC. Cancers, 2021, 13, 2139.	3.7	6
135	Real-Time Analysis of $\beta^2$ - and $\beta^3$ -Catenin mRNA Expression in ret/PTC-1 Activated and Nonactivated Thyroid Tissues. Diagnostic Molecular Pathology, 2003, 12, 44-49.	2.1	4
136	Correlation of integrated ERG/PTEN assessment with biochemical recurrence in prostate cancer. Cancer Treatment and Research Communications, 2021, 29, 100451.	1.7	4
137	Non-metastatic primitive peripheral neuroectodermal tumour of the kidney (extraskeletal Ewing's) Tj ETQq1 1 0.784314 rgBT /Overl	2.5	3
138	PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered?. Journal of Thoracic Oncology, 2016, 11, e142-e144.	1.1	3
139	Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer. International Journal of Cancer, 2020, 146, 2694-2702.	5.1	3
140	hsa_circ_0001275 Is One of a Number of circRNAs Dysregulated in Enzalutamide Resistant Prostate Cancer and Confers Enzalutamide Resistance In Vitro. Cancers, 2021, 13, 6383.	3.7	3
141	Quality-control issues for PCR-based assays in the molecular laboratory. Current Diagnostic Pathology, 2003, 9, 165-172.	0.4	2
142	Kidney Volume Correlates With Tumor Diameter in Renal Cell Carcinoma and Is Associated With Histological Poor Prognostic Features. International Journal of Surgical Pathology, 2014, 22, 39-46.	0.8	2
143	Predictive Values for Molecular Diagnostics: Converting Unknown Unknowns to Known Unknowns. Molecular Diagnosis and Therapy, 2014, 18, 1-4.	3.8	2
144	Diffuse oesophageal leiomyomatosis. ANZ Journal of Surgery, 2015, 85, 685-686.	0.7	2

#	ARTICLE	IF	CITATIONS
145	A Prospective Study of Aspirin Use and Prostate Cancer Risk by <i>TPMRSS2:ERG</i> Status. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 1231-1233.	2.5	2
146	Association of Prediagnostic Blood Metabolomics with Prostate Cancer Defined by ERG or PTEN Molecular Subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1000-1008.	2.5	2
147	Molecular Subtyping of Diffuse Large B-Cell Lymphoma Using a Novel Quantitative RT-PCR Assay. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 323-340.	2.8	2
148	Identification of potential therapeutic molecular targets preferentially expressed by esophageal cancer cells. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 267-269.	2.4	1
149	Can a biobank network and supporting infrastructure enhance Ireland's ability to attract pharmaceutical research and development and clinical trial opportunities? A pilot survey. <i>Journal of Biorepository Science for Applied Medicine</i> , 2016, , 1.	0.2	1
150	Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer. <i>Carcinogenesis</i> , 2020, 41, 904-908.	2.8	1
151	Gene Expression Pathways in Prostate Tissue Associated with Vigorous Physical Activity in Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 751-756.	2.5	1
152	Correction: Online Publication Dates for <i>Cancer Research</i> April 15, 2010 Articles. <i>Cancer Research</i> , 2010, 70, 4785-4786.	0.9	0
153	Application of statistical process control to qualitative molecular diagnostic assays. <i>Frontiers in Molecular Biosciences</i> , 2014, 1, 18.	3.5	0
154	Enzalutamide for treatment of CRPC: Rationale for sequencing and potential clinical biomarker for resistance. <i>Cancer Biology and Therapy</i> , 2015, 16, 201-203.	3.4	0
155	Genetic Susceptibility. <i>Molecular Pathology Library</i> , 2018, , 57-78.	0.1	0